1. Home
  2. BJDX vs AEMD Comparison

BJDX vs AEMD Comparison

Compare BJDX & AEMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bluejay Diagnostics Inc.

BJDX

Bluejay Diagnostics Inc.

HOLD

Current Price

$1.13

Market Cap

1.8M

Sector

Health Care

ML Signal

HOLD

Logo Aethlon Medical Inc.

AEMD

Aethlon Medical Inc.

HOLD

Current Price

$0.71

Market Cap

2.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BJDX
AEMD
Founded
2015
1984
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8M
2.1M
IPO Year
2021
2008

Fundamental Metrics

Financial Performance
Metric
BJDX
AEMD
Price
$1.13
$0.71
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$15.00
AVG Volume (30 Days)
403.8K
242.0K
Earning Date
05-12-2026
02-12-2026
Dividend Yield
N/A
N/A
EPS Growth
86.65
N/A
EPS
N/A
N/A
Revenue
$249,040.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.63
$0.51
52 Week High
$7.00
$5.89

Technical Indicators

Market Signals
Indicator
BJDX
AEMD
Relative Strength Index (RSI) 29.05 21.47
Support Level $0.63 $0.51
Resistance Level $2.02 $0.82
Average True Range (ATR) 0.56 0.17
MACD -0.45 -0.10
Stochastic Oscillator 2.56 4.06

Price Performance

Historical Comparison
BJDX
AEMD

About BJDX Bluejay Diagnostics Inc.

Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and quicker triage/treatment decisions.

About AEMD Aethlon Medical Inc.

Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment.

Share on Social Networks: